DDInter1313 DDInter1676
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Norfloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP1A1
Norfloxacin {u} (Compound) upregulates {v} (Gene) GHR
Norfloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Norfloxacin {u} (Compound) downregulates {v} (Gene) PRR7
Norfloxacin {u} (Compound) causes {v} (Side Effect) Paraesthesia
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ifosfamide
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Norfloxacin (Compound) resembles Gemifloxacin (Compound)
Norfloxacin (Compound) binds CYP1A1 (Gene)
Norfloxacin (Compound) upregulates GHR (Gene)
Norfloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Norfloxacin (Compound) downregulates PRR7 (Gene)
Norfloxacin (Compound) causes Paraesthesia (Side Effect)
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix